Alnylam Competitors and Similar CompaniesClear all
Celyad's competitors and similar companies include Sorrento Therapeutics, CureVac, Regulus Therapeutics and Ionis Pharmaceuticals.
 Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. |  Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. | ||
Founding Date | Founding Date 2007 | Founding Date 2006 | Founding Date 2000 | Founding Date 2007 | Founding Date 1989 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations San Diego, US HQ San Diego, US | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations San Diego, US HQ | Locations Carlsbad, US HQ |
Employees | Employees 17 | Employees 31019% decrease | Employees 999 | Employees 2462% decrease | Employees 92716% increase |
Valuation ($) | Valuation ($) 11.8 m | Valuation ($) 1.5 m | Valuation ($) 648.3 m | Valuation ($) 105.4 m | Valuation ($) 6.3 b |
Financial | |||||
Revenue (est.) | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) €53.8m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $787.6m (FY, 2023) |
Cost of goods | Cost of goods €69k (FY, 2023) | Cost of goods N/A | Cost of goods €64.3m (FY, 2023) | Cost of goods N/A | Cost of goods $9.1m (FY, 2023) |
Gross profit | Gross profit €1.4m (FY, 2023) | Gross profit N/A | Gross profit (€2.6m) (FY, 2023) | Gross profit N/A | Gross profit $778.5m (FY, 2023) |
Net income | Net income (€8.4m) (FY, 2023) | Net income ($577.8m) (FY, 2022) | Net income (€260.2m) (FY, 2023) | Net income ($30m) (FY, 2023) | Net income ($366.3m) (FY, 2023) |
Operating ⚠ | |||||
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued 233 (May, 2020) | Patents Issued 300 (FY, 2016) | Patents Issued N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 3 (May, 2020) | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2023) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised $ 1.1b | Total funding raised $ 10m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View company
CureVac
HQ
Tübingen, DE
Employees
999
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View companyRegulus Therapeutics
HQ
San Diego, US
Employees
24
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
View companyIonis Pharmaceuticals
HQ
Carlsbad, US
Employees
927↑ 16% increase
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
View company